Chronic Graft Versus Host Disease Clinical Trials

14 recruiting

Chronic Graft Versus Host Disease Trials at a Glance

15 actively recruiting trials for chronic graft versus host disease are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Seattle, Boston, and Tampa. Lead sponsors running chronic graft versus host disease studies include Fred Hutchinson Cancer Center, Dana-Farber Cancer Institute, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Browse chronic graft versus host disease trials by phase

Treatments under study

About Chronic Graft Versus Host Disease Clinical Trials

Looking for clinical trials for Chronic Graft Versus Host Disease? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Graft Versus Host Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Graft Versus Host Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

Chronic Graft Versus Host Disease
Sanofi37 enrolled29 locationsNCT07116031
Recruiting
Not Applicable

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

Acute Graft Versus Host DiseaseHematopoietic and Lymphatic System NeoplasmChronic Graft Versus Host Disease
Fred Hutchinson Cancer Center45 enrolled1 locationNCT07535008
Recruiting
Phase 2

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Chronic Graft Versus Host Disease
Northside Hospital, Inc.25 enrolled1 locationNCT06046248
Recruiting
Phase 2

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center50 enrolled3 locationsNCT07011810
Recruiting

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

Chronic Graft Versus Host Disease
M.D. Anderson Cancer Center8 enrolled1 locationNCT07127926
Recruiting
Phase 2

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center82 enrolled4 locationsNCT05996627
Recruiting
Phase 2

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Lung DiseasesBronchiolitis Obliterans SyndromeChronic Graft Versus Host Disease+1 more
Dana-Farber Cancer Institute45 enrolled5 locationsNCT05922761
Recruiting
Phase 1

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Chronic Graft Versus Host Disease
Stefanie Sarantopoulos, MD, PhD.30 enrolled1 locationNCT06233110
Recruiting
Phase 2

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphatic System NeoplasmChronic Graft Versus Host Disease
Mayo Clinic40 enrolled1 locationNCT06271616
Recruiting

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center300 enrolled10 locationsNCT04431479
Recruiting
Not Applicable

Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)

Chronic Graft Versus Host Disease
University Hospital, Bordeaux70 enrolled1 locationNCT06247150
Recruiting
Phase 1Phase 2

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

Chronic Graft Versus Host Disease
Yujun DONG24 enrolled1 locationNCT07012304
Recruiting
Phase 2

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

Chronic Graft Versus Host DiseasecGVHD
University of Miami49 enrolled1 locationNCT06663722
Recruiting
Phase 2

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Chronic Graft Versus Host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.52 enrolled12 locationsNCT06300320
Recruiting
Phase 2

A Phase II Study of the Impact of Two Different Schedules of Thymoglobulin on the Incidence of Extensive Chronic Graft Verus Host Disease (GVHD) in Patients Undergoing Unrelated Donor or Mismatched Related Donor Stem Cell Transplantation

Chronic Graft versus Host Disease in Haematology Malignancy Patients receiving donor stem cell transplantation
The Royal Melbourne Hospital120 enrolled1 locationACTRN12609000173291